Skip to main content
Sharon Savage, MD, Pediatric Hematology & Oncology, Bethesda, MD

SharonAnnSavageMD

Pediatric Hematology & Oncology • Bethesda, MD

Cancer Genetics/Cancer Risk Assessment, Pediatric Anemia and Red Blood Cell Hematology, Pediatric Hematologic Oncology

Director of the Clinical Genetics Branch, and Clinical Director of the Division of Cancer Epidemiology and Genetics, National Cancer Institute

Join to view full profile

Dr. Savage is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Savage's full profile

Already have an account?

  • Office

    10 Rockville Pike
    # National
    Bethesda, MD 20892
    Phone+1 240-276-7241

Summary

  • My internationally renowned research program combines clinical, genetic, and epidemiologic studies to advance understanding of cancer etiology and improve the lives of individuals with complex cancer-prone disorders.
    As Clinical Director of the Division of Cancer Epidemiology and Genetics (DCEG) at the NCI, I lead numerous strategic initiatives, oversee all clinical activities in the Division, ensure appropriate human subjects research protections, and provided thoughtful stewardship of research funding for all DCEG clinical activities. As Director of the Clinical Genetics Branch, I oversee 9 tenured PIs, 3 tenure-track investigators, and more than 40 clinical, technical, and administrative support personnel.
    I apply my expertise in genetics, clinical medicine, and epidemiology to discover the causes of cancer, understand the clinical manifestations of complex cancer-prone disorders, and apply these findings to individuals and populations at risk. Initiated in 2011, my Li-Fraumeni syndrome (LFS) study is an internationally recognized hub for > 900 participants and 14 international collaborative institutions and leads the field in understanding clinical and genetic aspects of LFS. My work in inherited bone marrow failure syndromes (IBMFS) has discovered 9 new causative genes and conducted unprecedented clinical phenotyping leading to changes in patient management. Nested within the IBMFS program, I have discovered 5 novel causes of dyskeratosis congenita/telomere biology disorders (DC/TBDs), defined new phenotypes, quantified cancer risk, and conducted the most comprehensive genotype-phenotype study, to date.

Education & Training

  • National Cancer Institute
    National Cancer InstitutePost-Doctoral Fellowship, 2000 - 2006
  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2000 - 2003
  • Children's National Hospital
    Children's National HospitalResidency, Pediatrics, 1997 - 2000
  • University of Vermont College of Medicine
    University of Vermont College of MedicineClass of 1997
  • Worcester Polytechnic Institute
    Worcester Polytechnic InstituteBS, Biochemistry, 1987 - 1991

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2000 - 2025
  • Pediatrics
    American Board of Pediatrics Pediatrics
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • This Rare Genetic Condition Leads to Cancer After Cancer
    This Rare Genetic Condition Leads to Cancer After CancerMay 17th, 2021
  • Establishing Links Between Germline Mutations and Oncogenesis
    Establishing Links Between Germline Mutations and OncogenesisSeptember 27th, 2017

Grant Support

  • Genetic Epidemiology Of Telomere Maintenance And Cancer EtiologyNational Cancer Institute2008
  • Genetic Epidemiology Of Telomere MaintenanceDivision Of Cancer Epidemiology And Genetics2006
  • Pharmacogenetic StudiesDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Pharmacogenetic StudiesDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Epidemiology and Genetics of Susceptibility to COVID-19 InfectionDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Intervention Trials in Persons at Increased Genetic Risk of CancerDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Clinical Genetic Studies of Familial and Hereditary Cancer SyndromesDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Family StudiesDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Intervention Trials in Persons at Increased Genetic Risk of CancerDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Clinical Genetic Studies of Familial and Hereditary Cancer SyndromesDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Family StudiesDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Family StudiesDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Epidemiology and Genetics of Susceptibility to COVID-19 InfectionDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Epidemiology and Genetics of Susceptibility to COVID-19 InfectionDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Epidemiology and Genetics of Susceptibility to COVID-19 InfectionDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Genetic Epidemiology of Telomere Maintenance and Cancer EtiologyDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent
  • Genetic Epidemiology of Telomere Maintenance and Cancer EtiologyDIVISION OF CANCER EPIDEMIOLOGY AND GENETICSPresent

External Links

  • Bibliographyhttps://www.ncbi.nlm.nih.gov/myncbi/sharon.savage.1/bibliography/public/

Dr. Sharon Savage, Dr. Sharon Savage, MD, Dr. S Savage, Dr. Sharon Ann Savage